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Abstract: 
The medicinal plant Echinacea is widely used to treat upper respiratory infections and is reported to stimulate 
the human immune system. A major constituent class of Echinacea, the alkyl-amides, has immunomodulatory 
effects. Recent studies show that alkylamides are oxidized by cytochrome P450 enzymes, but the 
immunomodulatory activity of these products is unknown. The objectives of this study were to characterize the 
products formed by incubation of an Echinacea extract and an isolated alkylamide with human liver 
microsomes, and to evaluate the influence of Echinacea alkylamides and metabolites on cytokine production by 
Jurkat human T cells. A novel class of carboxylic acid alkylamide metabolites was identified and shown to be 
the major constituents present after 2-h incubation of alkylamides with human liver microsomes. Echinacea 
alkylamides suppressed 1L-2 secretion by stimulated T cells, and this effect was significantly lessened upon 
oxidation of the alkylamides to carboxylic acids and hydroxylated metabolites. These findings highlight the 
importance of considering the influence of liver enzyme metabolism when evaluating the immunomodulatory 
effects of alkyl-amides. 
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Article: 
Introduction 
Echinacea, a genus native to the plains and prairies of North America, is among the most widely used plant 
medicines. Echinacea preparations constitute $300 million in annual sales in the USA [1], and physicians in 
Germany wrote more than three million prescriptions for Echinacea annually in the last decade [2]. Echinacea 
is reputed to beneficially stimulate the immune system and to aid in the treatment of upper respiratory infections 
[3]. Clinical trials have reported conflicting results as to the efficacy of Echinacea for this purpose [4], [5]. 
However, a vast body of research supports the assertion that Echinacea's constituents influence the human 
immune system [3]. 
 
Alkylamides comprise one of the major constituent classes that are associated with Echinacea's activity. In vitro 
studies have shown Echinacea alkylamides to have immunomodulatory effects, including upregulation of the 
expression of TNF mRNA by peripheral blood mononuclear cells [6], and suppression of the production of 
nitric oxide by cultured murine macrophages [7]. Alkylamides were also recently shown to regulate the 
expression of several cytokines in human whole blood [8]. In vivo, alkylamides have been shown to cause 
increased phagocytic activity of rat alveolar macrophages after oral administration [9]. Very little is known 
about the influence of alkylamides on T cells, key mediators in the immune response to upper respiratory infec-
tions, but a recent study found that alkylamides from Echinacea suppressed the secretion of the cytokine IL-2 
by cultured Jurkat human T-lymphocytes [10]. 
 
Recently, Matthias et al. demonstrated that the in vitro metabolism of alkylamides by human liver enzymes 
produces a number of metabolites [11]. Coker et al. observed degradation of caffeic acid derivatives in 
Echinacea preparations to result from treatment with microsomal fractions of human livers, and showed that 
both mutagenic and tumor cell metabolism enhancing effects of specific Echinacea preparations were increased 
after they were processed by the microsomes [12]. However, the influence of liver enzyme metabolism on the 
immunomodulatory effects of Echinacea alkylamides has not been reported. The goal of this study was to 
evaluate how structure and immunomodulatory activity of alkylamide constituents from Echinacea change in 
response to in vitro oxidation by human liver enzymes. The objectives of this study were to: 1) identify the 
products formed by enzymatic oxidation of alkylamides from Echinacea purpurea; 2) determine how the 
distribution of products varies as a function of time; and 3) investigate the influence of both native alkylamides 
and those oxidized by liver enzymes on cytokine production by cultured leukemic human T-lymphocytic cells. 
 
Materials and Methods 
Extract preparation 
Extracts were prepared from fresh cultivated roots of E. purpurea (Horizon. Herbs; Williams, OR, USA) within 
3 days of harvesting. A voucher specimen was collected and the species verified by Richard Cech (Owner, 
Horizon Herb). E. purpurea roots (1 g/2 mL solvent) were blended in ethanol (95%) and macerated at 4°C for 7 
days. The solvent was removed with a hydraulic press, and the extract was filter sterilized and stored at -70°C. 
The alkylamides were stable under these storage conditions for at least 12 months. Extracts at the dilution used 
for cell culture experiments were tested with the limulus amoebacyte lysate (LAL) assay (Cambrex 13ioscience; 
Rockland, ME, USA) and found to be free of endotoxin above 0.25 endotoxin units per ml. (EU/mL). 
 
Liver enzyme incubations 
Dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide (40 μM; Chromadex; Santa Ana, CA, USA) or E. 
purpurea extract (100 μL) were incubated with human liver microsomes in sterile phosphate buffer (pH 7.4, 0.1 
M). Pooled human liver microsomes (40 μL.; Moltox; Boone, NC, USA) were used with an assay concentration 
of 0.2 μM cytochrome P450 s. NADPH (1 mM) or sterile water was added to the appropriate samples or 
controls just before incubation at 37°C. Reagent grade ethanol (1:2.5) was added to stop the reactions, and the 
samples were centrifuged to precipitate proteins. Supernatants were filter-sterilized, the solvent was removed 
under vacuum at 35°C, and the samples were stored at -70°C. 
 
Analysis of alkylamides and metabolites 
The extracts were analyzed with a previously published liquid chromatography-mass spectrometry (LC-MS) 
method [13]. Separation was accomplished using reversed phase HPLC (HP1100 Agilent; Agilent; Palo Alto, 
CA, USA) with a linear acetonitrile/water gradient and a C18 column. An electrospray ionization mass 
spectrometer (Thermo Finnigan; San Jose, CA, USA) served as the detector. 
 
Quantitative analysis of dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide was conducted on triplicate 
supernatants from the microsome reactions. Samples concentrated 20-fold and resuspended in 5% ethanol 
(aqueous) were also quantified to verify solubility of the alkylamides. Linear regression on a calibration curve 
of peak area versus concentration of dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide yielded a coefficient 
of determination (R
2
) of 0.998. The concentrations of carboxylic acid metabolites in the samples were estimated 
based on this calibration curve, and were expressed as pg equivalent per mL (μg eq/mL) with an approach used 
previously for quantification of alkyl-amides in Echinacea [14]. While the resulting metabolite concentrations 
are only estimates, they can be used to compare the abundance of metabolites among samples. 
 
Cell culture followed by ELISA 
The Echinacea alkylamide samples from the microsome reactions were resuspended in 50 μL of 5% ethanol in 
media by vortexing, vigorously. The effects of the Echinacea alkylamides on IL-2 production by leukemic 
human T-lymphocytic cells (Jurkat E6.1 clone; ATCC; Manassas, VA, USA) were determined using a method 
described previously [10]. Briefly, the cells were plated at 10
5
 cells/mL and stimulated with phytohemagglutinin 
(PHA, 1 μg/mL) and phorbol 12-myristate 13-acetate (PMA, 1 ng/mL). The samples and controls were diluted 
10-fold into triplicate wells. Controls included cells with media alone, stimuli alone, and microsome reagents 
both with and without NADPH. The plates were incubated for 24 h before testing for IL-2 concentration by 
ELISA. 
 
Statistics 
IL-2 concentration data were subjected to one-way analysis of covariance (ANCOVA) using SPSS 14.0 (SPSS 
Inc.; Chicago IL, USA). Treatment (E. purpurea or alkylamide standard) was used as the main effect and 
dilutions were used as covariates. Multiple comparisons of main effects were adjusted by Bonferroni with an 
alpha value of 0.05. Mean values were calculated from triplicate wells, except in two cases where outliers were 
rejected (as justified by the Q-test) and the mean calculated for the remaining two data points. 
 
 
Results and Discussion 
Incubation with liver microsomes converted alkylamides in the E. purpurea extract to a number of metabolites. 
This is clearly demonstrated in Fig.1, which shows a chromatogram for an unmetabolized E. purpurea extract 
(a) and an extract that has been metabolized in vitro by human liver microsomes (b). The largest peak in Fig.la 
represents the most abundant alkylamides in. E. purpurea, the isomeric mixture of dodeca-2E,4E,8410E/Z-
tetraenoic acid isobutylamide [15]. The MS-MS fragmentation pattern and the HPLC retention time for this 
peak matched those of standard dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide. The other peaks in Fig. la 
represent less abundant alkylamides, as identified in Table 1. A total of 11 different alkylamides were identified 
in the extracts (Table 1), the structural assignments of which were made as described elsewhere [13]. The 
concentration of these alkylamides decreased after in vitro metabolism, and new peaks representing alkylamide 
metabolites were detected (Fig.lb). 
 
 
Three oxidized products were the major metabolites of dodeca2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide 
(Table 1, Fig. 2). These included hydroxylated and epoxide species, which have previously been reported as 
products of liver enzyme oxidation of alkylamides [11], and a novel carboxylic acid metabolite. A number of 
metabolites of the other minor alkylamides in the E. purpurea extract were also detected (Fig. 1), but due to the 
complexity of the extract, it was not possible to conclusively assign their alkylamide precursors. 
 
The assignments of alkylamide structures displayed in Fig. 2 are based on mass spectrometric fragmentation 
studies and existing literature. Matthias et al. convincingly demonstrated that the epoxide group on metabolite 
11e is located between carbons 8 and 9 [11]. Mass spectral fragmentation studies indicate that hydroxylation of 
the alkylamide does not occur on the N-isobutyl group, or on carbons 1-4, but the hydroxy group could be locat-
ed on any of carbons 4— 12. 
 
The identity of the new metabolite of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide as a carboxylic 
acid derivative was supported by the characteristic increase in mass of 30 Da, and the ability to detect the M — 
H
-
 ions of the metabolite (but not its alkylamide precursor) in negative ion mode LC-MS. Three primary 
carbons on dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutlyamide could be oxidized to carboxylic acids (Hg. 
2), one at the end of the unsaturated alkyl chain (C12), and two on the Nisobutyl group. The location of the 
carboxylic acid group on C12, as shown in Fig. 2, was supported by the MS-MS for the metabolite, which 
displayed a fragment at m/z = 74 consistent with an unmodified isobutylamine [13]. Studies of liver enzyme 
oxidation of standard isobutylamides further support the terminus of the alkyl chain as the location of the 
carboxylic acid group. Standard dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide produced both 
hydroxylated and carboxylic acid products upon incubation with microsomes, but standard undeca-2-ene-8,10- 
diynoic acid isobutylamide produced only hydroxylated and no carboxylic acid products. This difference is 
attributed to the terminus of undeca-2-ene-8,10-diynoic acid isobutylamide being blocked by an alkyne group, 
which prevents oxidation to the carboxylic acid. 
 
The concentrations of the major alkylamide (dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide) and its major 
metabolite (carboxylated dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide) in the samples used for 
immunmodulatory testing are displayed in Table 2. The conversion of the alkylamide to its products, as 
measured by the decrease in concentration of dodeca-2E,4E,8410Z-tetraenoic add isobutylamide, was less 
complete in the complex E. purpurea extract (79% conversion) than for the isolated alkylamide (90% 
conversion). An alkylamide with a terminal alkyne group was previously shown to inhibit the activity of 
cytochrome P450 enzymes [11]. The Echinacea extract used here contained three such compounds (alkylamides 
3, 4 and 7), which were likely responsible for the observed inhibition of enzyme activity observed for the 
complex extracts. 
 
The influence of incubation time on distribution of products formed by enzymatic oxidation of standard dodeca-
2E,4E,8Z,10Ztetraenoic add isobutylamide is demonstrated in. Fig. 3. At short incubation times (≤40 min), the 
most abundant product is the hydroxylated metabolite. Longer incubation (120 min) favors the carboxylic acid 
metabolite. After 120 min incubation with the liver microsomes, the majority of the alkylamide is converted to 
the carboxylic acid and hydroxylated metabolites. Thus, the 120 min incubation samples were utilized for cell 
culture assays. 
 
Fig. 4 shows the concentration of IL-2 secreted by stimulated cultured T-lymphocytes after concomitant 
treatment with various alkylamide samples (Table 2) and appropriate controls. The highest concentration of the 
E. purpurea extract (neat, 4 μg/mL of the major alkylamide dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobu-
tylamide) caused 47% suppression in IL-2 secretion as compared to microsome treatment alone. A significant 
suppressive effect (70% decrease in IL-2 concentration) was also observed for the highest concentration of 
standard dodeca-2E,4E,8Z,10Z-tetraenoic acid isohutylamide (1.8 μg/mL) as compared to the same control. 
These IL-2 suppressive effects were statistically significant for the highest concentration of both the E. purpurea 
extract (p = 0.020) and the alkylamide standard (p < 0.001). The 5-fold dilution of these samples did not induce 
a statistically significant suppression in IL-2, but a trend toward such an effect is evident. 
 
 
 
In contrast to the observation for the un metabolized alkylamide samples, a statistically significant suppression 
in IL-2 production was not observed for the NADPH containing E. purpurea and alkylamide samples, although 
a trend toward a suppressive effect was still evident (Fig. 4). Thus, the IL-2 suppressive effect of the 
alkylamides appears to be significantly lessened after liver enzyme metabolism. The remaining suppressive 
effect on IL-2 secretion observed for the E. purpurea and alkylamide samples + NADPH (Fig.4) could be due to 
the residual unoxidized alkylamides still present in the samples (Table 2), or to a slight suppressive effect of the 
alkylamide metabolites. 
 
 
The suppressive effect of E. purpurea alkylamides on IL-2 secretion by cultured T-lymphocytes observed in 
these studies (Fig.4) has been reported previously, and it has been shown that, in the micromolar concentration 
range, this effect is not due to cytotoxicity [9]. While the mechanism of IL-2 suppression is unknown, 
alkylamides are agonists of the cannabinoid receptor (CB2) [16] which is ubiquitous in immune cells (although 
at varying expression levels) [17]. Therefore, the IL-2 suppressive effect of unmetabolized alkylamides may be 
mediated by CB2. Other known CB2 agonists, including the anandamide congener 2-methylarachidonyl-(2'-
fluoroethyeamide, have been shown to suppress IL-2 expression in activated T cells; however, this activity has 
been reported to occur by a CB2-independent mechanism [18]. Further investigations are necessary to 
determine whether the observed IL-2 suppressive effect of alkylamides occurs through CB2 dependent or 
independent mechanisms. 
 
If CB2 binding were required for alkylamide mediated IL-2 suppression, the loss of this effect upon oxidation 
of alkylamides would be expected. Ligands of CB2 receptors possess unsaturated lipophilic chains that are 
necessary for the ligand/receptor interaction [18]. The action of liver enzymes on alkylamides introduces polar 
functionalities onto the unsaturated alkyl chains of alkylamides (Fig. 2), that likely would decrease their affinity 
for CB2 receptors. 
 
This study is the first to report a change in immunomodulatory activity of alkylamides in response to 
metabolism by liver enzymes. In this study, in vitro metabolism significantly lessened the IL-2 suppressive 
effects of alkylamides on T-lymphocytes. However, the alkylamide metabolites may have very different  
modulatory effects on other immune parameters, such as monocyte/macrophage activity. Alkylamides have 
been detected in the serum of patients who ingest Echinacea extracts [14], [20]. Therefore, studies of the 
immunomodulatory effects of alkylamides in their native form are still quite relevant. However, as 
demonstrated by the studies reported here, changes in immunomodulatory activity are likely to result as a 
consequence of liver metabolism, and are an important factor for consideration in future investigations of the 
mechanism of action of Echinacea and other alkylamide containing medicinal plants. 
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